Respiratory Health Division, National Institute for Occupational Safety and Health, Morgantown, WV, United States.
Front Public Health. 2021 Nov 4;9:744166. doi: 10.3389/fpubh.2021.744166. eCollection 2021.
Electronic cigarette, or vaping, products (EVP) heat liquids ("e-liquids") that contain substances (licit or illicit) and deliver aerosolized particles into the lungs. Commercially available oils such as Vitamin-E-acetate (VEA), Vitamin E oil, coconut, and medium chain triglycerides (MCT) were often the constituents of e-liquids associated with an e-cigarette, or vaping, product use-associated lung injury (EVALI). The objective of this study was to evaluate the mass-based physical characteristics of the aerosolized e-liquids prepared using these oil diluents. These characteristics were particle size distributions for modeling regional respiratory deposition and puff-based total aerosol mass for estimating the number of particles delivered to the respiratory tract. Four types of e-liquids were prepared by adding terpenes to oil diluents individually: VEA, Vitamin E oil, coconut oil, and MCT. A smoking machine was used to aerosolize each e-liquid at a predetermined puff topography (volume of 55 ml for 3 s with 30-s intervals between puffs). A cascade impactor was used to collect the size-segregated aerosol for calculating the mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD). The respiratory deposition of EVP aerosols on inhalation was estimated using the Multiple-Path Particle Dosimetry model. From these results, the exhaled fraction of EVP aerosols was calculated as a surrogate of secondhand exposure potential. The MMAD of VEA (0.61 μm) was statistically different compared to MCT (0.38 μm) and coconut oil (0.47 μm) but not to Vitamin E oil (0.58 μm); < 0.05. Wider aerosol size distribution was observed for VEA (GSD 2.35) and MCT (GSD 2.08) compared with coconut oil (GSD 1.53) and Vitamin E oil (GSD 1.55). Irrespective of the statistical differences between MMADs, dosimetry modeling resulted in the similar regional and lobular deposition of particles for all e-liquids in the respiratory tract. The highest (~0.08 or more) fractional deposition was predicted in the pulmonary region, which is consistent as the site of injury among EVALI cases. Secondhand exposure calculations indicated that a substantial amount of EVP aerosols could be exhaled, which has potential implications for bystanders. The number of EVALI cases has declined with the removal of VEA; however, further research is required to investigate the commonly available commercial ingredients used in e-liquid preparations.
电子烟或蒸气产品(EVP)加热液体(“电子液体”),其中包含物质(合法或非法)并将气溶胶颗粒输送到肺部。市售的油,如维生素 E 醋酸酯(VEA)、维生素 E 油、椰子油和中链甘油三酯(MCT),通常是与电子烟或蒸气产品使用相关的肺损伤(EVALI)相关的电子液体的成分。本研究的目的是评估使用这些油稀释剂制备的气溶胶化电子液体的基于质量的物理特性。这些特性是用于模拟区域呼吸沉积的气溶胶颗粒尺寸分布和用于估计输送到呼吸道的颗粒数的基于抽吸的总气溶胶质量。通过将萜烯分别添加到油稀释剂中来制备四种类型的电子液体:VEA、维生素 E 油、椰子油和 MCT。使用吸烟机以预定的抽吸形貌将每种电子液体气溶胶化(体积为 55ml,持续 3s,抽吸之间间隔 30s)。使用级联冲击器收集尺寸分离的气溶胶,以计算质量中值空气动力学直径(MMAD)和几何标准偏差(GSD)。使用多路径粒子剂量模型估计 EVP 气溶胶在吸入时的呼吸沉积。根据这些结果,计算 EVP 气溶胶的呼出分数作为二手暴露潜力的替代物。VEA 的 MMAD(0.61μm)与 MCT(0.38μm)和椰子油(0.47μm)相比,但与维生素 E 油(0.58μm)相比具有统计学差异;<0.05。与椰子油(GSD 1.53)和维生素 E 油(GSD 1.55)相比,VEA(GSD 2.35)和 MCT(GSD 2.08)观察到更宽的气溶胶粒径分布。无论 MMAD 之间是否存在统计学差异,剂量建模结果表明,所有电子液体在呼吸道中的颗粒的区域和叶沉积相似。预测在肺部区域的沉积分数最高(~0.08 或更高),这与 EVALI 病例中的损伤部位一致。二手暴露计算表明,大量的 EVP 气溶胶可能被呼出,这对旁观者有潜在影响。随着 VEA 的去除,EVALI 病例的数量有所下降;然而,需要进一步研究调查电子液体制剂中常用的市售成分。